Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1035.18% is 262% below its 5-year average of -286.19%, near the high end of its 5-year range (-18293.91%–16.71%).
75.18% above its 12-month average of -4171.42%.
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2020 (2020-09-30): -18293.91%.
EBITDA MARGIN
-1035.18%
EBITDA MARGIN AVG TTM
-4171.42%
EBITDA MARGIN AVG 3Y
-294.97%
EBITDA MARGIN AVG 5Y
-286.19%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+75.18%
CURRENT VS 3Y AVG
-250.95%
CURRENT VS 5Y AVG
-261.71%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Cogent Biosciences, Inc.
Market Cap
$5.27B
EBITDA Margin
-1035.18%
TTM Avg
-4171.42%
3Y Avg
-294.97%
5Y Avg
-286.19%
Market Cap
$5.20B
EBITDA Margin
21.06%
TTM Avg
20.50%
3Y Avg
18.63%
5Y Avg
16.67%
Market Cap
$5.20B
EBITDA Margin
-395.82%
TTM Avg
-536.17%
3Y Avg
-471.62%
5Y Avg
-471.62%
Market Cap
$5.53B
EBITDA Margin
-15636.44%
TTM Avg
-8457.23%
3Y Avg
-41454.98%
5Y Avg
-35632.55%
Market Cap
$5.02B
EBITDA Margin
9.15%
TTM Avg
-7.04%
3Y Avg
-33.99%
5Y Avg
-33.99%
Market Cap
$4.92B
EBITDA Margin
-8718.32%
TTM Avg
-5172.73%
3Y Avg
-3124.55%
5Y Avg
-2649.58%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | $5.27B | -1035.18% | -4171.42% | -294.97% | -286.19% |
| Doximity, Inc. (DOCS)vs › | $5.35B | 35.56% | 38.69% | 36.58% | 34.55% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.20B | 21.06% | 20.50% | 18.63% | 16.67% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.20B | -395.82% | -536.17% | -471.62% | -471.62% |
| Erasca, Inc. (ERAS)vs › | $5.11B | N/A | N/A | N/A | N/A |
| CRISPR Therapeutics AG (CRSP)vs › | $5.53B | -15636.44% | -8457.23% | -41454.98% | -35632.55% |
| BillionToOne, Inc. (BLLN)vs › | $5.02B | 9.15% | -7.04% | -33.99% | -33.99% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.92B | -8718.32% | -5172.73% | -3124.55% | -2649.58% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.81B | N/A | N/A | N/A | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.78B | -14.19% | -47.13% | -77.82% | -97.39% |
Gross Margin
0.0%
EBITDA Margin
-1035.2%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2020-09-30 | -18293.91% |
| 2020-06-30 | -1347.92% |
| 2020-03-31 | -83.15% |
| 2019-12-31 | 16.71% |
| 2019-09-30 | -1148.82% |
| 2019-06-30 | -325.37% |
| 2019-03-31 | -377.04% |
| 2018-12-31 | -227.39% |
| 2018-09-30 | -501.52% |
| 2018-06-30 | -547.06% |
| 2018-03-31 | -300.54% |
| 2017-12-31 | -309.61% |
| 2017-09-30 | -294.72% |
| 2017-06-30 | -276.43% |
| 2017-03-31 | -316.97% |
| 2016-09-30 | -17.86% |
| 2015-09-30 | -445.71% |
